Estimated glomerular filtration rate chronic slopes within placebo (A) in resistant hypertension, uncontrolled hypertension, and controlled hypertension and treatment effect of empagliflozin (B) in resistant hypertension, uncontrolled hypertension, and controlled hypertension. Estimated glomerular filtration rate slopes in resistant hypertension with and without mineralocorticoid receptor antagonist treatment (C) and treatment effect of empagliflozin on estimated glomerular filtration rate slopes in patients treated without (above) and with mineralocorticoid receptor antagonist. CI, confidence interval; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist